Abstract
Scleroderma is a descriptive construct that defines a large family of diseases characterized clinically by thickening of the skin. Systemic sclerosis (SSc) is a complex disease affecting multiple organ systems and is the most representative and prevalent of this spectrum of disorders. Generalized subcutaneous morphea (GSM, morphea profunda) is a form of localized scleroderma that tends to spare the internal organs. We are presenting two cases illustrating the aforementioned clinical entities.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Artlett, C., Microchimerism and Scleroderma: An Update. Current Rheumatology Reports, 2003. 5: p. 154–9.
Varga, J. and D. Abraham, Systemic sclerosis: A prototypic multisystem fibrotic disorder. Journal of Clinical Investigation, 2007. 117(3): p. 557–67.
Kahaleh, M., Raynaud phenomenon and the vascular disease in scleroderma. Current Opinion in Rheumatology, 2004. 16: p. 718–22.
LeRoy, E., et al., Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. Journal of Rheumatology, 1988. 15(2): p. 202–5.
Denton, C. and J. Korn, Digital ulceration and critical digital ischaemia in scleroderma. Scleroderma Care and Research Journal, 2003. 1: p. 12–6.
Steen, V. and T. Medsger, Changes in causes of death in systemic sclerosis, 1972–2002. Annals of Rheumatic Diseases, 2007. 66: p. 940–4.
Steen, V., et al., Isolated diffusing capacity reduction in systemic sclerosis. Arthritis and Rheumatism, 1992. 35(7): p. 765–70.
Tashkin, D., et al., Cyclophosphamide versus placebo in scleroderma lung disease. New England Journal of Medicine, 2006. 25(354): p. 2655–66.
Zamora, A., et al., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respiratory Medicine, 2008. 1(102): p. 150–5.
Nihtyanova, S., C. Black, and C. Denton, Mycophenolate mofetil in diffuse cutaneous systemic sclerosis – A retrospective analysis. Rheumatology, 2007. 3(46): p. 442–5.
Peterson, L., A. Nelson, and W. Su, Classification of morphea (localized scleroderma). Mayo Clinic Proceedings, 1995. 70: p. 1068–76.
Person, J. and W. Su, Subcutaneous morphoea: A clinical study of sixteen cases. British Journal of Dermatology, 1979. 100: p. 371–80.
Dehen, L., et al., Internal involvement in localized scleroderma. Medicine (Baltimore), 1994. 73(5): p. 241–5.
Postlethwaite, A., et al., Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. Journal of Clinical Investigation, 1992. 90(4): p. 1479–85.
Igarashi, A., et al., Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. Journal of Investigational Dermatology, 1996. 106(4): p. 729–33.
Uziel, Y., et al., Methotrexate and corticosteroid therpay for pediatric localized scleroderma. Journal of Pediatrics, 2000. 136: p. 91–5.
Grundman-Kollmann, M., et al., PUVA-cream photochemotherapy for the treatment of localized scleroderma. Journal of the American Academy of Dermatology, 2000. 43(4): p. 675–8.
Martini, G., et al., Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology, 2009. 48(11): p. 1410–3.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Schiopu, E., Seibold, J.R. (2010). Scleroderma. In: Mahmoudi, M. (eds) Challenging Cases in Allergic and Immunologic Diseases of the Skin. Springer, New York, NY. https://doi.org/10.1007/978-1-60761-296-4_18
Download citation
DOI: https://doi.org/10.1007/978-1-60761-296-4_18
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-60761-295-7
Online ISBN: 978-1-60761-296-4
eBook Packages: MedicineMedicine (R0)